Patrick Durisch (@dbdurisch.bsky.social) (@DBdurisch) profile picture

Health Policy - Politique Santé Public Eye (formerly the Berne Declaration)

Lausanne, Switzerland
Joined September 2013
Photo by Patrick Durisch (@dbdurisch.bsky.social) (@DBdurisch)Photo by Patrick Durisch (@dbdurisch.bsky.social) (@DBdurisch)Photo by Patrick Durisch (@dbdurisch.bsky.social) (@DBdurisch)Photo by Patrick Durisch (@dbdurisch.bsky.social) (@DBdurisch)Photo by Patrick Durisch (@dbdurisch.bsky.social) (@DBdurisch)Photo by Patrick Durisch (@dbdurisch.bsky.social) (@DBdurisch)Photo by Patrick Durisch (@dbdurisch.bsky.social) (@DBdurisch)Photo by Patrick Durisch (@dbdurisch.bsky.social) (@DBdurisch)Photo by Patrick Durisch (@dbdurisch.bsky.social) (@DBdurisch)Photo by Patrick Durisch (@dbdurisch.bsky.social) (@DBdurisch)
Nos enquêtes ont révélé des marges bénéficiaires gigantesques réalisées par la #pharma en🇨🇭. Le potentiel d’économie est énorme sur les médicaments très chers – sans pour autant mettre en péril l’innovation, l’approvisionnement ou leur viabilité financière publiceye.ch/fr/coin-medias/…
55
Patrick Durisch (@dbdurisch.bsky.social) retweeted
A new book by @realtahiramin and Rohit Malpani is now available in the U.S. Pharma Monopoly: The Battle for the Future of Medicines examines the origins of outdated patent rules and economic policies that champion monopolies over the public interest. 🔗wiley.com/en-us/Pharma+Monop…
4
9
286
Patrick Durisch (@dbdurisch.bsky.social) retweeted
In this excerpt from Chapter 5 of Pharma Monopoly, titled “The Innovation Trap,”  we explain how the pharmaceutical industry has weaponized the word “innovation” to ensure a perpetual novelty of knowledge that should be in the public domain.
6
4
357
Patrick Durisch (@dbdurisch.bsky.social) retweeted
The WHO is deciding this now. EU & Norway are to blame but they can change course. We need a fair & equitable pathogen access and benefit-sharing system 🌍 #fairpabs Sign fairpabs.org
1
30
A virus or bacteria's digital sequence information uploaded by a public lab in Recife or Nairobi re-emerges as intellectual property owned in the US or Europe. No trace. No obligation. No return. This injustice cannot go on. Sign the petition fairpabs.org #fairpabs
33
Patrick Durisch (@dbdurisch.bsky.social) retweeted
Excellent @ICIJorg longform piece on #pharma drug pricing - specifically focused #Merck's secretive pricing of its blockbuster drug Keytruda. icij.org/investigations/canc… Worth flagging this part of it:
1
4
4
1,706
Thank you @realtahiramin @IMAKglobal for supporting @PublicEyeSuisse in our patent analysis of cancer drug #Keytruda, in conjunction with @ICIJorg, unveiling Merck/MSD's gaming of the patent systems to maintain overinflated prices & delay competition publiceye.ch/en/topics/pharm…
Replying to @realtahiramin
What @ICIJorg found aligns with what we, and others, have found: Merck has built a multi-pronged patent abuse scheme to fortify its Keytruda monopoly and maintain high prices.
2
2
5
442
Patrick Durisch (@dbdurisch.bsky.social) retweeted
Este medicamento puede salvar vidas, pero se vende hasta dos veces más caro en #Guatemala que en Europa. Mientras la farmacéutica Merck gana millones, pacientes con cáncer deben pelear contra el sistema para acceder a Keytruda, #LaMedicinaDelMillón. 💊 lnk.bio/s/a2daf
2
69
4
84
12,581
Patrick Durisch (@dbdurisch.bsky.social) retweeted
💸¿Por qué un fármaco contra el cáncer de #Merck es inaccesible para muchos pacientes? #Pembrolizumab (Keytruda) cuesta US$65.000 por terapia en Perú si lo cubre el SIS, y el doble el privado. Una investigación de @ICIJorg, que integra #SaludConLupa, revela el negocio detrás.🧵
5
85
88
6,345
Patrick Durisch (@dbdurisch.bsky.social) retweeted
The Trump administration is using U.S. trade power and extreme tariffs to bully other countries into binding agreements that undermine affordable and readily available access to medicines. Experts from around the world offer an alternate vision:
3
12
2
12
2,673
Plutôt une vaste farce qu'un accord, un peu comme les soldes : des % en apparence élevés mais sur des prix catalogue fictifs, avec un impact mineur pour les patient·e·s 🇺🇸 mais majeur pour #BigPharma. Qui exigera en retour une hausse indécente en🇨🇭🇪🇺... rts.ch/info/economie/2025/ar…
1
36